Research Background The core focus of this study is the manifestation of gray matter atrophy in neuroinflammatory diseases. Gray matter atrophy typically appears in four types of neuroinflammatory demyelinating diseases: Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD) positive (AQP4+) and negative (AQP4-) for aquaporin-4 an...

This is a multicenter retrospective cohort study on the impact of oral corticosteroid dosage and tapering duration on the time to first relapse in patients with initial presentation of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). Background: MOGAD is a unique antibody-associated demyelinating disease. In both children an...

This study revolves around the protein arginine methyltransferase PRMT9, revealing its important role in acute myeloid leukemia (AML) and its potential as an anticancer target. Researchers found that PRMT9 expression levels were significantly elevated in AML stem cells and leukemic cells. Through gene editing and chemical probes, they discovered th...

This study utilized a machine learning framework to explore the underlying cell states and cellular ecosystems constituting soft tissue sarcomas, and associated them with patient prognosis and response to immunotherapy. Research Background: Soft tissue sarcomas are rare and highly heterogeneous malignancies of connective tissues, with limited syste...

In this study, researchers explored the role of the TAK1 activation pathway in CAR T cell therapy-associated immune effector cell-associated neurotoxicity syndrome (ICANS). They established a mouse ICANS model and found that following the transfer of CAR19 T cells, cerebellar cells were activated, underwent morphological changes, and expressed more...

Utilizing Dynamic Single-Cell Analysis to Discover a Clinically Effective Chimeric Antigen Receptor T-Cell Subset for Treating Diffuse Large B-Cell Lymphoma Research Background Chimeric antigen receptor (CAR) T-cell therapy has been proven to be an effective treatment for B-cell malignancies. However, it remains challenging to predict individual cl...

Immunotherapy Drives Mesenchymal Transition and Tumor Microenvironment Immune Response in Glioblastoma Introduction Glioblastoma is a highly malignant brain tumor with no curative treatment currently available. Although immunotherapy has shown efficacy in other cancer types, the response in glioblastoma patients is limited. Investigating the effect...